<SEC-DOCUMENT>0001213900-17-007665.txt : 20180629
<SEC-HEADER>0001213900-17-007665.hdr.sgml : 20180629
<ACCEPTANCE-DATETIME>20170717172043
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0001213900-17-007665
CONFORMED SUBMISSION TYPE:	CORRESP
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20170717

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			American BriVision (Holding) Corp
		CENTRAL INDEX KEY:			0001173313
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				260014658
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		CORRESP

	BUSINESS ADDRESS:	
		STREET 1:		11 SAWYERS PEAK DRIVE
		CITY:			GOSHEN
		STATE:			NY
		ZIP:			10924
		BUSINESS PHONE:		845-551-8728

	MAIL ADDRESS:	
		STREET 1:		11 SAWYERS PEAK DRIVE
		CITY:			GOSHEN
		STATE:			NY
		ZIP:			10924

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	METU BRANDS, INC.
		DATE OF NAME CHANGE:	20150908

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ECOLOGY COATINGS, INC.
		DATE OF NAME CHANGE:	20080821

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Ecology Coatings, Inc.
		DATE OF NAME CHANGE:	20070711
</SEC-HEADER>
<DOCUMENT>
<TYPE>CORRESP
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: Red">&nbsp;<IMG SRC="img_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 20pt 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 20pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">July
17, 2017</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>VIA
EMAIL AND MAIL</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Suzanne
Hayes</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assistant
Director</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office
of Healthcare and Insurance</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; text-align: left; padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Re:</B></FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>American
                                         Brivision (Holding) Corporation</B></FONT></TD>
</TR>     <TR STYLE="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="text-align: left; padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Amendment
                                         No. 3 to Registration Statement on Form S-1</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="text-align: left; padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Filed
                                         May 24, 2017</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="text-align: left; padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>File
                                         No. 333-213618</B></FONT></P>



</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dear
Ms. Hayes:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
letter is in response to the letter dated June 14, 2017 from the staff (the &ldquo;Staff&rdquo;) of the Securities and Exchange
Commission (the &ldquo;Commission&rdquo;) addressed to American Brivision (Holding) Corporation (the &ldquo;Company&rdquo;, &ldquo;we&rdquo;
or &ldquo;our&rdquo;). For ease of reference, we have repeated the Commission&rsquo;s comments in this response and numbered them
accordingly. An amended Registration Statement on Form S-1/A submitted accompanying this Response Letter is referred to as Amendment
No. 4.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Risk
Factors</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>We
are highly dependent on our license agreement with BioLite, page 6</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
your updated disclosure on your BioLite collaboration agreement on page 26, you state that one of the amendments made pursuant
to the January 2017 addendum is that the royalty percentage may be renegotiated in case BioLite is obligated to pay its licensor
in excess of 3% of the net sales. If true, please clarify in this risk factor and in the Business section that the rights you
license from BioLite are not owned by BioLite but licensed by BioLite from a third party. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I</FONT>n
response to Staff&rsquo;s comments, the Registration Statement has been revised. Please refer to the revised disclosure on pages
6, 25, and 35 of Amendment No. 4.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Business</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Collaborative
Agreement with BioLite, page 35</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
refer to your statement in the second bullet on page 36 and elsewhere that you own all Compound IP to the extent such data were
developed in North America. However, you state in clause (3) of the last bullet on this page that the ownership of any clinical
trial data and Intellectual Property (as defined in your collaborative agreement) shall belong to you. Please reconcile these
disclosures so that the ownership of such clinical trial data is clear in your prospectus without referring investors to the agreement
itself.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
response to Staff&rsquo;s comments, the Registration Statement has been revised. Please refer to the revised disclosure on pages
26, 35, 36 and 53 of Amendment No. 4.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Business</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Our
Products, page 37</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Please
revise the descriptions of each of your completed and in-process clinical trials to describe the endpoints. It is not sufficient
to state that the trial included endpoints related to efficacy. For completed trials, discuss the results with respect to the
trial endpoints.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
response to Staff&rsquo;s comments, the Registration Statement has been revised. Please refer to the revised disclosure on pages
37&ndash;42 of Amendment No. 4.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Please
kindly note that we are citing statement regarding the endpoints and conclusions from the report published by Memorial Sloan Kettering
Cancer Center (&ldquo;MSKCC&rdquo;), and we are not allowed to provide further explanations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;<B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Please
explain your statement on page 40 that &ldquo;Neither primary nor secondary endpoint will be determined until ABV-1504 Phase II
Part II Trials are completed.&rdquo; It is not clear how you can conduct clinical trials without knowing what the endpoints are.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
response to Staff&rsquo;s comments, the Registration Statement has been revised. Please refer to the revised disclosure on pages
40 and 42 of Amendment No. 4.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B></FONT></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Please
update your disclosure in the sixth bullet on page 37 regarding whether you have begun the Phase II clinical trial for ABV-1501
since the first quarter of 2017 has now passed.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
response to Staff&rsquo;s comments, the Registration Statement has been revised. Please refer to the revised disclosure in the
bullet point starting with &ldquo;We are currently negotiating&rdquo; on page 37 of Amendment No. 4.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;With
respect to ABV-1501 and ABV-1502, we note that the referenced website describes the primary endpoint as a statistically significant
improvement in neutrophil count and neutrophil function. Please revise your disclosure indicating that the primary endpoint is
to describe changes in neutrophil count and function to further clarify.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
response to Staff&rsquo;s comments, the Registration Statement has been revised. Please refer to the revised disclosure on pages
37 and 38 of Amendment No. 4.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Please
kindly note that we are citing statement regarding the endpoints and conclusions from the report published by MSKCC, and we are
not allowed to provide further explanations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Please
update your disclosure to state whether you have received an IND for ABV-1502.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
response to Staff&rsquo;s comments, the Registration Statement has been revised. Please refer to the revised disclosure in the
bullet point starting with &ldquo;Currently, we have commenced&hellip;&rdquo; on page 38 of Amendment No. 4.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Your
discussion of product candidate ABV-1503 on page 39 references a Phase II trial and states that you are currently preparing the
IND package for ABV-1503. Please clarify whether all preclinical and Phase I trials for this product have been completed, and
whether the IND will only relate to a Phase II trial. If the Phase I trial has been completed, please disclose where it was conducted,
and the primary and secondary endpoints of the trial and whether they were met.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I</FONT>n
response to Staff&rsquo;s comments, the Registration Statement has been revised. Please refer to the revised disclosure in bullet
point starting with &ldquo;Phase I Trial for ABV-1503 is unnecessary &hellip;&rdquo; and in bullet point starting with &ldquo;For
ABV-1503, we are currently preparing&hellip;&rdquo; on page 40 of Amendment No. 4.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
note your revised disclosure in response to comment 9. We refer to your statement in the third full paragraph on page 41 that
the Phase II Part I trial for ABV-1505 has been completed, and your statement in the following paragraph that you are in the process
of negotiating a clinical trial agreement for both portions of the Phase II trials. Please reconcile these disclosures, and if
the Phase II Part I trial has been completed, please disclose whether the primary endpoint of safety has been met.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
response to Staff&rsquo;s comments, the Registration Statement has been revised. Please refer to the revised disclosure in the
bullet point starting with &ldquo;As mentioned above, BioLite has&hellip;&rdquo; on page 41 of Amendment No. 4.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Executive
Compensation</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Outstanding
Equity Awards at Fiscal Year End, page 49</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Please
further update your revised table to disclose the vesting date of the stock award in a footnote, and to reflect the dollar value
of the stock award using the closing market price of your stock at the end of the last fiscal year. Refer to Instructions 2 and
3 to Item 402(p)(2) of Regulation S-K.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
response to Staff&rsquo;s comments, the Registration Statement has been revised. Please refer to the revised disclosure on page
51 of Amendment No. 4.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Please
be kindly advised that we issued the stocks on February 17, 2016, and there is no vesting schedule.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Certain
Relationships and Related Transactions, and Director Independence, page 50</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.&nbsp;&nbsp;&nbsp;&nbsp;We
acknowledge your revised disclosure in response to comment 16. However, we note you have deleted the previously disclosed transaction
with YuangGene Corporation, the company controlled by your CEO, which should still be disclosed in this section since the transaction
occurred since October 1, 2015. Please also explain the nature of the relationship with BioLite in this section. Prefer to Item
404(a) of Regulation S-K.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
response to Staff&rsquo;s comments, the Registration Statement has been revised. Please refer to the revised disclosure on pages
52-53 of Amendment No. 4.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9642;&#9642;&#9642;&#9642;&#9642;&#9642;&#9642;&#9642;&#9642;&#9642;&#9642;&#9642;&#9642;&#9642;&#9642;&#9642;&#9642;&#9642;&#9642;&#9642;&#9642;&#9642;&#9642;&#9642;&#9642;&#9642;&#9642;&#9642;&#9642;&#9642;&#9642;&#9642;&#9642;&#9642;&#9642;&#9642;&#9642;&#9642;&#9642;&#9642;&#9642;&#9642;&#9642;&#9642;&#9642;&#9642;&#9642;&#9642;&#9642;&#9642;&#9642;&#9642;&#9642;&#9642;&#9642;&#9642;&#9642;&#9642;&#9642;&#9642;&#9642;&#9642;&#9642;&#9642;&#9642;&#9642;&#9642;&#9642;&#9642;&#9642;&#9642;&#9642;&#9642;&#9642;&#9642;&#9642;&#9642;&#9642;&#9642;&#9642;&#9642;&#9642;&#9642;&#9642;&#9642;&#9642;&#9642;&#9642;&#9642;&#9642;&#9642;&#9642;&#9642;&#9642;&#9642;&#9642;&#9642;&#9642;&#9642;&#9642;&#9642;&#9642;&#9642;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
responding to your comments, the Company acknowledges that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company
    is responsible for the adequacy and accuracy of the disclosure in the filing;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Staff comments
    or changes to disclosure in response to Staff comments do not foreclose the Commission from taking any action with respect
    to the filing; and</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company
    may not assert Staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities
    laws of the United States.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
appreciate the assistance the Staff has provided with its comments. If you have any questions, please do not hesitate to call
our counsel, Joan Wu, Esq. of Hunter Taubman Fischer &amp; Li LLC, at (212) 732-7184.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 265.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 265.5pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 60%; padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 40%; padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sincerely,</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kira Huang</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial
    Officer</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">American
    Brivision (Holding) Corporation</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 265.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0; text-indent: 0; width: 7%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">cc:</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; width: 93%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joan Wu,
    Esq.</FONT></TD></TR>
</TABLE>







<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0; font: 10pt Times New Roman, Times, Serif">5</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>img_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "% 8 # 2(  A$! Q$!_\0
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M\,>!H=>6QL=<\7Z1J GMKO1M0LHX[JVMEFN(08W,+K*W](Y_:K\7%FQ^Q?\
MM@GDX/\ PC7P3 /TS\=/RKZ^HKQL'D\,#7QV(PV*KQEF&(>)KQG3P]2*G>;4
M:?-!2C!<\M&Y-JUV?+99PO2R?&9QC<OS'%TZF=XUX_%PJT,%B*<:S=9J-#GA
M3E"FO;324G.5E&\M-?D#_AJOQ=_T9=^V#_X3?P2_^?K_ )Y]L_0GPX\:WWQ
M\+V_B34?A]X\^&-U/=WMJWA3XD6GAVQ\46Z6<YA2]G@\+^)/%>D"SOE'GV31
MZQ+.T)!N(+>3,8[NBO3ITZL97GB)58V:Y'2H05W:SYJ:4M-=-G?79'OT:.)I
MRO5QLL1'E:Y'A<+1U=K2YZ+<_=L_=^%WUV04445L=04444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M=;:%:^(?H_XK_$?XL^&/VH_V7OAQX9UWP7:_#/XM6/Q@?QUI>K^#-2U3Q?\
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MX)R?\%!+#]MCX;66G?$7P2_P-_:H\)^ OAWXV^+GP*U.]6Z0>%?B7X?MM?\
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M9K6#7;_5]0U+U_X6?#;2?A'X)TGX>^'=7\3:KX8\.>?:>&(?%FLR>(=3\/\
MAXS,^E>%;;6[N(:MJ&B>'+9ETO0&UV[U76+72+>SL+K5KV.T@92B@#T.N+^(
M_@#PK\5O 'C3X9>.--&K^#O'_AC6O!_B;3?->W>ZT7Q!83Z9?I;W416>SNUM
M[AY+*^MV2YL;M(;NVDCGAC=2B@#R/Q%^RI\)/$%]XKU.VL-1\-7_ ([T#X-^
M$?'%UX?N+)&\5^"/@AKNJ:_X2\%ZI!JNGZK9IH&IIK=]X>\7K8VUIJ7B+PNT
M&BSZC!!:VCP1:G^S#X8N?$WQ-\4>'_&WC[P0?B\WAN;QKX;\,2^##X-U"Z\/
M>#M4\ W-Z?#6O>#-<L;B\\3>#]0L=&\22:H-2BNAX5\'WEE!87>A1RW!10!F
M67[(7PYTSP5\;_A_HWB#QUI'AWX\Z1X7T'Q#'9ZEH4EUX8T;PA\+_"WP>TJP
M\%SWWAN\%DC^!_!NBVEW-KT?B*XEU$7>I)+%+<!(^J_X9W\.'QGKGCD^+/&A
MU3Q%\7O"?QKU&T:;PR=,'B;P9\,M,^$UAI5K"?#'VJ#PW?>&-)L+C4K7[:^J
M-K4<M]9:Q8P3R61** ,.3]DGX.0:YXI\3^&].UKP3XE\5?$[2/C.FL>%=9FL
M_P#A&/BMIF@:MX7O/&WA+2;V+4- T:^\6^'M>U[2_'VE+I,WASQNNO\ B&^\
M1:-?:IXAUR^U&UK_ .S!X1\5^$/B3X7\0^+/'%_K/Q;O/!UYX]^("7'ABR\7
M:JO@.XTJ?PS8V<%IX6B\(:1I]A'I:VOV?3O"L)EBO=1GDD:_NOMB%% '3^(/
M@CI.J^-M<^(WA?Q;XQ^&OC'Q;X<T;PMXUU?P3-X=QXOT7PY+J<WATZM8>*?#
MGB;38=<\/KK>KVND>)]+L]/UZ"POVT^>^NK*TTR"QYG0?V4_@YH7A7Q9X _L
M*;6OAIXS\!>%OAQJOP\U^6VU+P\F@^$Y_$EW%>PWC6D7B:?Q+K6K>*M7\0:[
MXEU+7[_6+KQ))#XAM;JRUA)+R4HH T-!_9[TC0/A+K_P-7QOXZU+X<ZM\,M+
M^$NB6>JZAIFH^(?"OA73_ R^!+ZZL_%%_I5UJ>M^)=>MVDUK5M=\4'6I9];<
MW8MP'N$N,CP_^R_X5T/_ (5G<7WC3X@>)[_X.Z!IOA?X:7VO77A/_BEO#UBF
MC:=JME;Z9I7A'3-"O;_Q=X:TA/!GB?Q)J.E77B63PEJ6N:1HFK:&-:U"><HH
M O:%^SCHOAGP[IG@SP]\0OB;I'@+PW!-!\/_  =::SH+V'P[;[-?VFA'P[JM
MWX9NO$>I6/@M;]9/!F@^,M9\4>'-#;3-%A&D7-EH^G6MO]"0QF*&*)I99VBB
MCC,\Y0S3&- AFF,:11F60C?(8XXT+LQ5$7"@HH DKY_^)G[-?PZ^+VJ:[J/C
M]_$&L0:Z?A(T>EP:C;Z3;:%<?!GQ=XB\:>&[O0=0TJPL_$%I-K-_XKU_2/&$
M<^M7=KK_ (6U.\\-R6UOI=]J$-X44 <8?V._!<&HZGJVC?$+XK>'M0U'X@?&
M_P")4%WI.L^%1/HWB'X_Z"?#_C!-&EOO!M[):6.D(\^J^$(Y&GNM(UB=KB\O
M-5MDALXV^)?V,_AAX@DT1M+UGQEX%AT7X/)\"KVS\$W'A?3+3Q1X!M?$'A7Q
M)IL/B6/4/"FJO>ZOHU]X4^SZ-JEM)9R:;IWB?QG:6\0_X2*>6$HH WH?V4?A
MMIVOQ>(_"^I>,/"&IK\:?%_QXN_[%UBSN;/4?&/CKP)XF\ ^)M,NK/7]*UF&
M'P=?VOC#Q!XE'AG3!I]K#XUU"X\2)(+FYO([GVCX?^#;/X=>!O!WP_T[4M6U
MC3?!'AC0_">FZIKKZ?)K-[IWA_3H-)T^?5)=*T_2=/FOC9VD"W,UIIME#-*K
?2BWC9VR44 =?1110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
